Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $67.6 million.

  • Summit Therapeutics' Total Non-Current Liabilities rose 699.19% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.6 million, marking a year-over-year increase of 699.19%. This contributed to the annual value of $45.2 million for FY2024, which is 6347.31% down from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Total Non-Current Liabilities is $67.6 million, which was up 699.19% from $62.8 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Total Non-Current Liabilities high stood at $536.1 million for Q4 2022, and its period low was $19.7 million during Q3 2022.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $63.2 million (2024), whereas its average is $96.0 million.
  • Per our database at Business Quant, Summit Therapeutics' Total Non-Current Liabilities skyrocketed by 186267.48% in 2022 and then tumbled by 7692.62% in 2023.
  • Quarter analysis of 5 years shows Summit Therapeutics' Total Non-Current Liabilities stood at $27.3 million in 2021, then surged by 1862.67% to $536.1 million in 2022, then crashed by 76.93% to $123.7 million in 2023, then tumbled by 63.47% to $45.2 million in 2024, then soared by 49.7% to $67.6 million in 2025.
  • Its Total Non-Current Liabilities was $67.6 million in Q3 2025, compared to $62.8 million in Q2 2025 and $37.8 million in Q1 2025.